SEC Form 4 · accession 0001209191-17-053902
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J. Weiland
Director
Period of report
Sep 22, 2017
Accepted (ET)
Sep 26, 2017 · 9:39 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.47 | Sep 22, 2017 | A | 7,500 | A | — | Sep 21, 2027 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person.